Genomma gets a cash injection
This article is powered by OTC Bulletin & The Rose Sheet
Executive Summary
Mexican OTC medicines and personalcare specialist Genomma Lab has secured an investment package of almost US$100 million (€85 million) to help fund the ongoing construction of a production plant in its home country.
You may also be interested in...
$60m For Mexico’s Genomma From World Bank Group’s Private Sector Arm
IFC, the private sector arm of the World Bank Group, has loaned $60m to Mexican Pharmaceutical Genomma, building on its long track record in Latin American health investments.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.